Roundtable: Insight on Case-by-Case Reviews of Various Regulatory Submissions

Time: 10:00 am
day: Day Two

Details:

There are currently over 209 companies in Europe developing regenerative medicines and ATMPs. In lieu of this however, there are only 11 EMA-approved gene therapies in the market. To gain an insight into best practices navigating regulatory hurdles during various stages of the gene therapy development process, we will dive deeper into some gene therapy success stories, facilitated by the following regulatory affairs specialists:

Speakers: